The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD
Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324. Online ahead of print.
Mary P Moore12, Rory P Cunningham12, Grace M Meers12, Sarah A Johnson13, Andrew A Wheeler4, Rama R Ganga4, Nicole M Spencer4, James B Pitt4, Alberto Diaz-Arias5, Ahmed I A Swi3, Ghassan M Hammoud3, Jamal A Ibdah123, Elizabeth J Parks23, R Scott Rector123
Author information
Research Service, Harry S Truman Memorial Veterans Medical Center, Columbia, MO, USA, 65201.
Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, USA, 65211.
Department of Medicine-Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA, 65211.
Department of Surgery, University of Missouri, Columbia, MO, USA, 65211.
Boyce & Bynum Pathology Professional Services, Columbia, MO, 65201, USA.
Abstract
Background and aims: Nonalcoholic fatty liver disease (NAFLD) and its more advanced form steatohepatitis (NASH) is associated with obesity and is an independent risk factor for cardiovascular, liver-related, and all-cause mortality. Available human data examining hepatic mitochondrial fatty acid oxidation and hepatic mitochondrial turnover in NAFLD and NASH are scant. To investigate this relationship, liver biopsies were obtained from patients with obesity undergoing bariatric surgery and data clustered into four groups based on hepatic histopathological classification: Control (no disease), NAFL (steatosis only), Borderline-NASH (steatosis with lobular inflammation or hepatocellular ballooning), and Definite-NASH (steatosis, lobular inflammation, and hepatocellular ballooning).
Results: Hepatic mitochondrial complete fatty acid oxidation to CO2 and the rate limiting enzyme in β-oxidation (β-hydroxyacyl-CoA dehydrogenase activity) were reduced by ~40-50% with D-NASH compared with Control. This corresponded with increased hepatic mitochondrial reactive oxygen species production, as well as dramatic reductions in markers of mitochondrial biogenesis, autophagy, mitophagy, fission and fusion in NAFL and NASH.
Conclusions: These findings suggest that compromised hepatic fatty acid oxidation and mitochondrial turnover are intimately linked to increasing NAFLD severity in patients with obesity.